Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

L.S. Schwartzberg; K. Tauer; J. Atkins; K. Sivarajan; V. Patel; B. Bastos; C. Langer; M.A. Socinski; D.R. Spigel

doi:10.1016/S0923-7534(20)34340-4

Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

L.S. Schwartzberg, K. Tauer, J. Atkins, K. Sivarajan, V. Patel, B. Bastos, C. Langer, M.A. Socinski, D.R. Spigel

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Annals of Oncology
Volume	23
DOIs	https://doi.org/10.1016/S0923-7534(20)34340-4
State	Published - Sep 1 2012

Disciplines

Gastroenterology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1016/S0923-7534(20)34340-4License: Unspecified

Cite this

Schwartzberg, L. S., Tauer, K., Atkins, J., Sivarajan, K., Patel, V., Bastos, B., Langer, C., Socinski, M. A., & Spigel, D. R. (2012). Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology, 23. https://doi.org/10.1016/S0923-7534(20)34340-4

Schwartzberg, LS, Tauer, K, Atkins, J, Sivarajan, K, Patel, V, Bastos, B, Langer, C, Socinski, MA & Spigel, DR 2012, 'Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)', Annals of Oncology, vol. 23. https://doi.org/10.1016/S0923-7534(20)34340-4

@article{cbb32177351c4b8a9bf121439fcdeabc,

title = "Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)",

author = "L.S. Schwartzberg and K. Tauer and J. Atkins and K. Sivarajan and V. Patel and B. Bastos and C. Langer and M.A. Socinski and D.R. Spigel",

note = "CET added to platinum doublet chemotherapy (chemo) improves survival in advanced NSCLC (Pirker R, et al. Lancet 2009). However, the optimal chemo combination with CET is not established for either squamous cell (SQ) or non-squamous (NSQ) histology. eLung was an open-label randomized phase II study in SQ & NSQ cohorts of patients (pts) with advanced NSCLC.",

year = "2012",

month = sep,

day = "1",

doi = "10.1016/S0923-7534(20)34340-4",

language = "American English",

volume = "23",

journal = "Annals of Oncology",

}

TY - JOUR

T1 - Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

AU - Schwartzberg, L.S.

AU - Tauer, K.

AU - Atkins, J.

AU - Sivarajan, K.

AU - Patel, V.

AU - Bastos, B.

AU - Langer, C.

AU - Socinski, M.A.

AU - Spigel, D.R.

N1 - CET added to platinum doublet chemotherapy (chemo) improves survival in advanced NSCLC (Pirker R, et al. Lancet 2009). However, the optimal chemo combination with CET is not established for either squamous cell (SQ) or non-squamous (NSQ) histology. eLung was an open-label randomized phase II study in SQ & NSQ cohorts of patients (pts) with advanced NSCLC.

PY - 2012/9/1

Y1 - 2012/9/1

UR - https://www.sciencedirect.com/science/article/pii/S0923753420343404

U2 - 10.1016/S0923-7534(20)34340-4

DO - 10.1016/S0923-7534(20)34340-4

M3 - Article

VL - 23

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Disciplines

Access to Document

Other files and links

Cite this